Zacks: Brokerages Anticipate Aura Biosciences, Inc. (NASDAQ:AURA) Will Announce Earnings of -$0.44 Per Share

Wall Street brokerages expect that Aura Biosciences, Inc. (NASDAQ:AURAGet Rating) will announce ($0.44) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Aura Biosciences’ earnings. The company is expected to announce its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Aura Biosciences will report full-year earnings of ($2.03) per share for the current year. For the next financial year, analysts anticipate that the company will report earnings of ($2.76) per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Aura Biosciences.

Separately, Zacks Investment Research upgraded shares of Aura Biosciences from a “sell” rating to a “hold” rating in a report on Thursday. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $33.25.

Shares of NASDAQ AURA opened at $17.90 on Thursday. Aura Biosciences has a 12 month low of $13.50 and a 12 month high of $26.16. The business’s 50-day moving average price is $19.34.

Institutional investors have recently added to or reduced their stakes in the stock. New York State Common Retirement Fund purchased a new stake in Aura Biosciences in the fourth quarter valued at approximately $45,000. Medicxi Ventures Management Jersey Ltd purchased a new stake in Aura Biosciences in the fourth quarter valued at approximately $51,617,000. Marshall Wace LLP acquired a new position in Aura Biosciences during the fourth quarter valued at approximately $66,000. Deutsche Bank AG acquired a new position in Aura Biosciences during the fourth quarter valued at approximately $56,000. Finally, Wells Fargo & Company MN acquired a new position in Aura Biosciences during the fourth quarter valued at approximately $55,000. Hedge funds and other institutional investors own 51.69% of the company’s stock.

About Aura Biosciences (Get Rating)

Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.

Read More

Get a free copy of the Zacks research report on Aura Biosciences (AURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.